Growth of Nuclear Medicine Industry & Radiopharmaceuticals 2017

1
Nuclear Medicine Market Radiopharmaceuticals
SPECT/PET Radioisotopes (Technetium, F-18),
Beta/Alpha radiation therapy (I131, Y-90),
Applications (Cancer/Oncology, Cardiac)
Stable Isotopes (Deuterium, C-13) - Global Trends
Forecast to 2017
Published Date April 2013
No. of Pages 360
Price Single User US4650
Corporate User US7150
2
New Market Research Report on Nuclear Medicine
Market Radiopharmaceuticals SPECT/PET
Radioisotopes (Technetium, F-18), Beta/Alpha
radiation therapy (I131, Y-90), Applications
(Cancer/Oncology, Cardiac) Stable Isotopes
(Deuterium, C-13) - Global Trends Forecast to
2017 added to ReportsnReports.com
The market of radiopharmaceuticals is dominated
by diagnostic radioisotopes, comprising of SPECT
and PET radioisotopes. The lions share of the
SPECT market is taken up by Tc-99m, whereas the
PET market is dominated by F-18FDG isotope.
Furthermore, the PET market will witness a double
digit growth during the forecast period. The
therapeutic segment contributes only 10 to the
global radiopharmaceuticals market and I-131 has
been considered as the gold standard for various
oncology treatments in a combined therapy. Global
nuclear medicines market is majorly driven by the
increasing adoption of PET and SPECT scanners,
and rising awareness for radiopharmaceuticals,
whereas short half life of isotopes and stringent
regulations are the factors that are hindering
the growth of radiopharmaceuticals
worldwide. Besides highly preferred isotopes
such as Tc-99m and F-18, significant growth is
witnessed for Tl-201 and Rb-82 in diagnostic
market and Y-90 and Lu-177 in beta therapy
radioisotopes market. Exhaustive pipeline
analysis reveals that coronary heart disease,
Alzheimers disease, breast cancer, and bone
metastasis will drive the diagnostic
radiopharmaceuticals market, whereas lymphoma,
prostate cancer, bone metastasis, and
hepatocellular carcinoma will boost the future of
therapeutic radiopharmaceuticals. Besides new
applications, the potential molecules that are
expected to drive the market include Alpharadin
(Ra-223), Ga-68, F-18 florbetapir, and F-18
choline. Though Ra-223 application is still under
clinical trial, the market is highly optimistic
regarding its clinical efficiency in prostate
cancer, and bone metastasis.
3
Nuclear Medicine Market Radiopharmaceuticals
SPECT/PET Radioisotopes (Technetium, F-18),
Beta/Alpha radiation therapy (I131, Y-90),
Applications (Cancer/Oncology, Cardiac)
Stable Isotopes (Deuterium, C-13) - Global Trends
Forecast to 2017
North America held the largest share in the
global radiopharmaceuticals market. The U.S.
market is highly supported by the Mo-99
production of NRU reactor (Canada) and ongoing
researches in different clinical institutes such
as National Cancer Institute, Avid
Radiopharmaceuticals and so on. Besides developed
markets, the Asia-Pacific region is expected to
show a remarkable growth in the coming years.
China, India, Japan, South Korea, Brazil, and
South Africa are expected to show a high growth
potential amongst the emerging geographies. These
countries are influenced by the domestic
production of isotopes by reactors and government
initiatives. Apart from upcoming isotopes and
their applications, understanding of the
interlinked supply chain was imperative for
market estimation. Value chain analysis and
pipeline analysis have taken care of such
business issues to come up with a consolidated
market analysis, including the present and future
impact of different factors. Demand and supply
analysis identifies the potential risk of the
interrupted supply of Mo-99 for the Tc-99m
production, due to scheduled shutdown of major
reactors and the benchmarking trend adopted by
leading players to combat such operational
difficulties. Buy a copy of report _at_
http//www.reportsnreports.com/purchase.aspx?name
232420 .
Browse more research reports on Pharmaceuticals_at_
http//www.reportsnreports.com/market-research/pha
rmaceuticals/ .
4
Nuclear Medicine Market Radiopharmaceuticals
SPECT/PET Radioisotopes (Technetium, F-18),
Beta/Alpha radiation therapy (I131, Y-90),
Applications (Cancer/Oncology, Cardiac)
Stable Isotopes (Deuterium, C-13) - Global Trends
Forecast to 2017
Major Points from Table of Contents 10 Company
Profiles (Overview, Financials, Products
Services, Strategy, Developments)10.1
Companies10.1.1 Bracco Imaging S.P.A.10.1.2
Cambridge Isotope Laboratories, Inc.10.1.3
Cardinal Health, Inc.10.1.4 Covidien, Plc10.1.5
Eczacibasi-Monrol10.1.6 Fujifilm Holdings
Corporation10.1.7 Ge Healthcare (Subsidiary Of
General Electric Company)10.1.8 Iba Group10.1.9
Isotec, Inc. (Sigma-Aldrich)10.1.10 Lantheus
Medical Imaging, Inc.10.1.11 Nordion,
Inc.10.1.12 Ntp Radioisotopes (PTY),
Ltd.10.1.13 Petnet Solutions, Inc. (A Subsidiary
Of Siemens Medical Solutions Usa, Inc.)10.1.14
Taiyo Nippon Sanso Corporation Inquire for
discount _at_ http//www.reportsnreports.com/contacts
/discount.aspx?name232420 .
5
About ReportsnReports
ReportsnReports.com is your single source for all
market research needs. Our database includes
250,000 syndicated market research reports from
100 leading global publishers covering in-depth
analysis of over 5000 micro markets. With
comprehensive information about the publishers
and their report methodology, data sources, etc.
we help you in your purchase decision by mapping
your information needs with the most relevant
available reports in our library. Connect with
us sales_at_reportsandreports.com 1 888 391 5441
Contact sales_at_reportsandreports.com for further
information.
Contact sales_at_reportsandreports.com for further
information.